CVS Health Corporation (NYSE:CVS) is among the cheap healthcare stocks to buy heading into 2026. On December 4, Bernstein SocGen Group raised its price target on CVS Health Corporation (NYSE:CVS) to $86.00 from $77.00, while reaffirming its ‘Market Perform’ rating on the stock. The firm attributed the improved guidance to the company’s Aetna business unit, while acknowledging lingering pressures in its Pharmacy Benefit Manager (PBM) segment.
According to Bernstein, CVS Health Corporation (NYSE:CVS) is “executing its turnaround very well,” but the complexities around the PBM environment cannot be ignored. This means that near-term EPS growth will be negatively affected.
Pixabay/Public domain
Aetna is what the company describes as “an attractive growth engine” for CVS Health Corporation (NYSE:CVS), stating that PBM growth can resume along with drug spending growth. Bernstein further added that “uncertainty in PBM’s near-term earnings growth” offsets “Aetna’s strong momentum.”
The same day, RBC Capital maintained its Outperform rating and $93 price target on CVS Health Corporation (NYSE:CVS) ahead of the company’s Investor Day presentation, scheduled for Tuesday, December 9. The analyst highlighted the company’s strong position as the market transitions toward zero-reimbursement pharmacy benefit manager (PBM) models.
CVS Health Corporation (NYSE:CVS) is a healthcare solutions provider based in Rhode Island in the United States. Incorporated in 1996, the company operates through three segments: healthcare benefits, health and pharmacy services, and consumer wellness.
While we recognize CVS’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: The best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money.
Disclosure: None.